Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Impact · against what's priced in

Akari Therapeutics has hit a key de-risking milestone by initiating GMP manufacturing and partnering with WuXi XDC for its AKTX-101 program. While the move toward a Phase 1 trial is positive, the clinical initiation timeline is distant (late 2026 or early 2027), limiting the immediate price impact.

AKTX+0.40

No priced-in read yet